

June 12, 2024
Fuji Pharma Co., Ltd.

**Conclusion of License and Supply Agreement of FSN-013
in Two ASEAN Countries (Vietnam and Philippines)**

Fuji Pharma Co., Ltd. (“Fuji”) announced that Fuji’s subsidiary, OLIC (Thailand) Limited (“OLIC”) concluded a License and Supply Agreement of Nextstellis™ (“Product”, Development code: FSN-013, marketed in Thailand for the indication of “contraception” since April 2023) with Lupin Limited (“Lupin”), a global pharma major, in Vietnam and Philippines (Multicare Pharmaceuticals Philippines, Inc. (“Multicare”), a subsidiary of Lupin, in Philippines) , for marketing.

According to the agreement, OLIC will procure the Product from Mithra Pharmaceuticals SA (Headquarters; Liege, Belgium) and provide to Lupin.

Product combines the native and selective estrogen, estetrol (E4) with drospirenone (DRSP). Estetrol has been confirmed to act selectively on estrogen receptors, and this selectivity is expected to provide a variety of benefits to patients. The oral contraceptive market in the six major ASEAN countries is estimated at about 28 billion yen, with Thailand accounting for about 50%, the Philippines for 23%, and Vietnam for 12%.

Nextstellis™ is the first product of Fuji Pharma Group marketed outside Japan. By launching the Product in Thailand, OLIC has expanded its business from a pure CMO company to a new hybrid company with CMO and pharmaceutical business with its own brand products. With this conclusion of this agreement, Fuji Pharma Group can expand its business into the two Southeast Asian countries other than Thailand through OLIC.

We are continuing discussions with potential partners regarding the marketing of this product in major Southeast Asian countries other than Thailand, Vietnam, and the Philippines.

We will continue to contribute well-being of women around the world by offering excellent pharmaceuticals.

[About Mithra Pharmaceuticals SA]

Mithra (Euronext: MITRA) is a biotech company headquartered in Liège, Belgium, dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. In particular, Mithra are exploring the potential of estetrol, a natural estrogen, not only for women's medicine but also for a wide range of other applications. Mithra is currently developing our second estetrol product, Donesta[®], a next-generation formulation of hormonal therapy, after launching our first estetrol-based product, the oral contraceptive Estelle[®], in 2021. It offers partners a complete initial development through clinical development and specialist manufacturing of Polymeric forms for Complex Therapeutics (vaginal rings, implants), Sterile injectables and Biomedicine (vials, prefilled syringes, cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members.

For further information, please visit our website www.mithra.com.

[About Lupin Limited]

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector. Please visit www.lupin.com for more information.

Note

The financial forecasts and other projections provided in this release are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks. Actual results may differ significantly from these forecasts for a number of reasons. It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification. Information in this release about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsks@fujipharma.jp